Furthermore, the approval of dimethyl fumarate (BG-12), another NRF2 activator, for use in the treatment of multiple sclerosis [50] is the confirmation of NRF2 being a viable drug target in disease. This evidence concerns the gene NFE2L2 and multiple sclerosis.